Skip to main content

Neurovascular Diseases

During 2023 we have continued to develop research projects and train researchers in stroke disease but also developing new lines of research in vascular dementia and Alzheimer\\\’s disease. All of this with a very translational vision with specific projects in patient cohorts and in vivo and in vitro experimental models, highlighting extensive national and international collaborations with other research groups and biotech/pharma companies with relevant results in high-impact journals. More specifically, we have continued using transcriptomics and proteomics data sets identifying molecules that might be considered as biomarkers & therapeutic targets of stroke, we have tested different therapeutic strategies in pre-clinical models of Stroke and Alzheimer’s Disease in own projects but also in collaboration with pharmaceutical companies, investigated the effects of air pollutants on stroke disease and cognitive impairment, and monitoring biomarkers in several stroke clinical trials. 

eCORE

  • Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation
  • Brain & Mind and Behaviour
  • Chronic, Prevalent Diseases & Aging

Team

Group Leader
Anna Rosell Novel

Principal Investigator (PI)
Mar Hernández, Pilar Delgado, Olga Maisterra, Joan Montaner

Researchers
Anna Bonaterra, Toni Palasí, Alejandro Ballvé

PhD Students
Paula Garcia, Berta Páez, Marta Klimczak, Daisy Guamán

Lab Technicians
Anna Penalba, Miguel García, Júlia Valor, Kerrie Adrián, Laia Fernández, Itsasne de la Torre

Nursing and Technical Staff
Jesús Pizarro, Marcel Lamana, Belén Gutiérrez, Diana Liébana, Eva Ruiz

Publications

22
Publications
68.2
%Q1
250.50
Impact Factor
11.39
Average Impact Factor

Arrue M, Penalba A, Rodriguez-Bodero A, Elicegui A, de Homdedeu M, Cruz MJ, Simats A, Rodriguez S, Buxo X, Garcia-Rodriguez N, Pizarro J, Turner MC, Delgado P, Rosell A A.
Diesel exhaust particles exposure exacerbates pro-thrombogenic plasma features ex-vivo after cerebral ischemia and accelerates tPA-induced clot-lysis in hypertensive subjects.
Journal of Cerebral Blood Flow and Metabolism, 2023, 2023 Nov 16:271678X. 231214826.
DOI: 10.1177/0271678X231214826
IF: 6.3

Sole M, Marazuela P, Castellote L, Bonaterra-Pastra A, Gimenez-Llort L, Hernandez-Guillamon Sole M, Marazuela P, Castellote L, Bonaterra-Pastra A, Hernandez-Guillamon M.
Therapeutic effect of human ApoA-I-Milano variant in aged transgenic mouse model of Alzheimer’s disease.
British Journal of Pharmacology, 2023, 180(15):1999-2017.
DOI: 10.1111/bph.16065
IF: 7.3

Hernandez-Guillamon M.
Implications of a pathophysiological framework for cerebral amyloid angiopathy.
Lancet Neurology, 2023, S1474-4422(23)00196-5.
DOI: 10.1016/S1474-4422(23)00196-5
IF: 48

Machado-Pereira M, Grayston A, Garcia-Gabilondo M, Francisco V, Cristovao A, Marto J, Vieira H, Viana-Baptista M, Ferreira L, Bernardino L, Rosell A, Ferreira R.
Retinoic Acid-Loaded Nanoparticles Promote Neurovascular Protection in Stroke.
Stroke, 2023, 54:e149–e151.
DOI: 10.1161/STROKEAHA.122.041839
IF: 8.4

Duperron MG, Knol MJ, Le Grand Q, Evans TE, Mishra A, Tsuchida A, Roshchupkin G, Konuma T, Tregouet DA, Romero JR, Frenzel S, Luciano M, Hofer E, Bourgey M, Dueker ND, Delgado P, Hilal S, Tankard RM, Dubost F, Shin J, Saba Y, Armstrong NJ, Bordes C, Bastin ME, Beiser A, Brodaty H, Bulow R, Carrera C, Chen C, Cheng CY, Deary IJ, Gampawar PG, Himali JJ, Jiang J, Kawaguchi T, Li S, Macalli M, Marquis P, Morris Z, Munoz Maniega S, Miyamoto S, Okawa M, Paradise M, Parva P, Rundek T, Sargurupremraj M, Schilling S, Setoh K, Soukarieh O, Tabara Y, Teumer A, Thalamuthu A, Trollor JN, Valdes Hernandez MC, Vernooij MW, Volker U, Wittfeld K, Wong TY, Wright MJ, Zhang J, Zhao W, Zhu YC, Schmidt H, Sachdev PS, Wen W, Yoshida K, Joutel A, Satizabal CL, Sacco RL, Bourque G, Lathrop M, Paus T, Fernandez-Cadenas I, Yang Q, Mazoyer B, Boutinaud P, Okada Y, Grabe HJ, Mather KA, Schmidt R, Joliot M, Ikram MA, Matsuda F, Tzourio C, Wardlaw JM, Seshadri S, Adams HHH, Debette S, Le Grand Q
Genomics of perivascular space burden unravels early mechanisms of cerebral small vessel disease.
Nature Medicine, 2023, 29(4):950-962
DOI: 10.1038/s41591-023-02268-w
IF: 82.9

Projects

Testing the endovascular route for improved neuroprotection and neurorepair in stroke recovery.
Principal Investigator: Anna Rosell
Agency: Instituto de Salud Carlos III (PI22/01055)
Funding: 141,570 €
Period: 2023-2025

ELAPSE-ND: European-Latin American and Caribbean collaborative project on personalized medicine for neurological disorders.
Principal Investigator: Mar Hernández Guillamon
Agency: nstituto de Salud Carlos III-4th EU-LAC Joint Call in STI (AC22/00051)
Funding: 174,845 €
Period: 2023-2025

RICORS-ICTUS. Redes Temáticas RICORS-Enfermedades Vasculares Cerebrales.
Principal Investigator: Anna Rosell
Agency: Instituto de Salud Carlos III (RD21/0006/0007)
Funding: 250,215 €
Period: 2022-2024

Implicaction of proteins associated with vascular beta-amyloid in Cerebral Amyloid Angiopathy.
Principal Investigator: Mar Hernandez Guillamon
Agency: Instituto de Salud Carlos III (PI20/00465)
Funding: 169,400 €
Period: 2021-2023

PRESTIGE-AF: PREvention of STroke in Intracerebral hemorrhaGE survivors with Atrial Fibrillation.
Principal Investigator: Joan Montaner
Agency: European Comission (H2020SC12017)
Funding: 481,723 €
Period: 2017-2023

Patents

Method for selecting a patient for a reperfusion therapy
Priority Number: PCT/EP2020/063726
Priority Date: 15/05/2020
Applicants: VHIR

Methods and compositions for treating ischemia in a subject
Priority Number: EP21382021.0 ES
Priority Date: 15/01/2021
Applicants: 90% VHIR / 10% ANAXOMICS

VHIR Annual Report 2023